discovers, develops, and commercializes multivariate protein diagnostics based on its proprietary mass spectrometry-based discovery platform. VeriStrat, a multivariate serum protein test, is Biodesix’s first product developed with this technology. The commercially available test provides oncologists with information to help them select between erlotinib and single-agent chemotherapy for advanced lung cancer patients. Tests are processed in Biodesix’s CLIA-certified laboratory and results are reported in less than 72 hours. In addition to developing novel diagnostics independently, the company also partners with biotechnology and pharmaceutical companies to develop companion diagnostics to improve the utility of therapeutic agents.